In the latest trading session, 2,852,700 Marker Therapeutics, Inc.(NASDAQ:MRKR) shares changed hands as the company’s beta touched 1.28. With the company’s most recent per share price at $1.78 changing hands around $0.31 or 0.21% at last look, the market valuation stands at $84.04 Million. MRKR’s current price is a discount, trading about -90.45% off its 52-week high of $3.39. The share price had its 52-week low at $1.32, which suggests the recent value is25.84% up since then. When we look at Marker Therapeutics, Inc.’s average trading volume, we note the 10-day average is 306.88 Million shares, with the 3-month average coming to 275.37 Million.
Analysts gave the Marker Therapeutics, Inc. (MRKR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.5. If we narrow down to specifics, the data shows that none out of 2 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended MRKR as a Hold, 2 felt it is a Buy and none rated the stock as Underweight. Marker Therapeutics, Inc.’s EPS for the current quarter is expected to be -$0.16.
Instantly MRKR is in green as seen in intraday trades today. With action 20.85%, the performance over the past five days has been green. The jump to weekly highs of $2.19 on Tuesday, Jan 05 added 18.04% to the stock’s daily price. The company’s shares are showing year-to-date upside of 0.24%, with the 5-day performance at 0.14% in the green. However, in the 30-day time frame, Marker Therapeutics, Inc. (NASDAQ:MRKR) is 0.06% up. Looking at the short shares, we see there were 3.43 Million shares sold at short interest cover period of 0.01 days.
The consensus price target for the stock as assigned by Wall Street analysts is $7, meaning bulls need an upside of 293.26% from its recent market value. According to analyst projections, MRKR’s forecast low is $6 with $8 as the target high. To hit the forecast high, the stock’s price needs a +349.44% upsurge from its latest level, while the stock would need to tank 237.08% for it to hit the projected low.
Marker Therapeutics, Inc. (MRKR) estimates and forecasts
Data shows that the Marker Therapeutics, Inc. share is not performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value dive -25.76% over the past 6 months, a -25.53% in annual growth rate that is considerably lower than the industry average of 16.4%. But despite this, analysts have looked to lower expectations by downgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Marker Therapeutics, Inc. will drop -45.5%, while the growth in revenue is estimated to hit -21.4% for the next quarter. Year-over-year growth is forecast to reach 125.4% up from the last financial year.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 54.4%. The 2021 estimates are for Marker Therapeutics, Inc. earnings to increase by 93.9%, but the outlook for the next 5-year period is at 0% per year.
Marker Therapeutics, Inc. (NASDAQ:MRKR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 29.88% of Marker Therapeutics, Inc. shares while 29.82% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 42.54%. There are 87 institutions holding the Marker Therapeutics, Inc. stock share, with NEA Management Company, LLC the top institutional holder. As of Sep 29, 2020, the company held 10.41% of the shares, roughly 5Million MRKR shares worth $7.5 Million.
Aisling Capital Management LP holds the second largest percentage of outstanding shares, with 4.16% or 2Million shares worth $3Million as of Sep 29, 2020.
Among Mutual Funds, the top two as of Sep 29, 2020 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 862737 shares estimated at $1.29 Million under it, the former controlled 1.8% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.24% of the shares, roughly 594.86 Thousand shares worth around $1.01 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.